$FOMX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Foamix Pharmaceuticals Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Foamix Pharmaceuticals Ltd.. Get notifications about new insider transactions in Foamix Pharmaceuticals Ltd. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 3.53 | 12,719 | 44,898 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 3.53 | 12,719 | 44,898 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 5.06 | 24,947 | 126,232 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 5.06 | 24,947 | 126,232 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 4.76 | 21,562 | 102,635 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 4.76 | 21,562 | 102,635 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Sell | D | 0.00 | 21,212 | 0 | 0 | 21.2 K to 0 (-100.00 %) |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Sell | D | 0.00 | 21,212 | 0 | 0 | 21.2 K to 0 (-100.00 %) |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Sell | D | 0.00 | 21,147 | 0 | 21,212 | 42.4 K to 21.2 K (-49.92 %) |
| Mar 18 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Sell | D | 0.00 | 21,147 | 0 | 21,212 | 42.4 K to 21.2 K (-49.92 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.06 | 100,000 | 406,000 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | D | 4.06 | 100,000 | 406,000 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 78,799 | 0 | 0 | 78.8 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 78,799 | 0 | 0 | 78.8 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 35,275 | 0 | 78,799 | 114.1 K to 78.8 K (-30.92 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Sell | D | 0.00 | 35,275 | 0 | 78,799 | 114.1 K to 78.8 K (-30.92 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 3.77 | 75,997 | 286,509 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 3.77 | 75,997 | 286,509 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 6.35 | 30,000 | 190,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 6.35 | 30,000 | 190,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 5.39 | 13,000 | 70,070 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 5.39 | 13,000 | 70,070 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 8.54 | 40,000 | 341,600 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | D | 8.54 | 40,000 | 341,600 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 91,303 | 0 | 0 | 91.3 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 91,303 | 0 | 0 | 91.3 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 12,333 | 0 | 91,303 | 103.6 K to 91.3 K (-11.90 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | D | 0.00 | 12,333 | 0 | 91,303 | 103.6 K to 91.3 K (-11.90 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 5.02 | 24,883 | 124,962 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 5.02 | 24,883 | 124,962 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 4.69 | 21,435 | 100,466 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 4.69 | 21,435 | 100,466 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 11.87 | 24,000 | 284,849 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | D | 11.87 | 24,000 | 284,849 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Sell | D | 0.00 | 112,200 | 0 | 0 | 112.2 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Sell | D | 0.00 | 112,200 | 0 | 0 | 112.2 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 10.80 | 3,000 | 32,403 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 10.80 | 3,000 | 32,403 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 5.88 | 8,000 | 47,032 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Option Exercise | D | 5.88 | 8,000 | 47,032 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 43,030 | 0 | 0 | 43 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 43,030 | 0 | 0 | 43 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 15,714 | 0 | 43,030 | 58.7 K to 43 K (-26.75 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | D | 0.00 | 15,714 | 0 | 43,030 | 58.7 K to 43 K (-26.75 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 5.02 | 49,766 | 249,825 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 4.69 | 82,153 | 385,298 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 59,016 | 0 | 0 | 59 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 182,500 | 0 | 59,016 | 241.5 K to 59 K (-75.56 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Sell | D | 0.00 | 52,842 | 0 | 241,516 | 294.4 K to 241.5 K (-17.95 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 3.77 | 70,297 | 265,020 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | D | 6.35 | 50,000 | 317,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | D | 0.00 | 85,490 | 0 | 0 | 85.5 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | D | 0.00 | 12,742 | 0 | 85,490 | 98.2 K to 85.5 K (-12.97 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 4.03 | 96,365 | 388,351 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 3.81 | 94,996 | 361,935 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.40 | 35,093 | 224,595 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 5.22 | 196,205 | 1,024,190 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 10.31 | 60,389 | 622,611 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.34 | 60,000 | 380,400 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 7.13 | 202,004 | 1,440,289 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 6.77 | 18,000 | 121,860 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 5.46 | 24,125 | 131,723 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | D | 1.92 | 5,469 | 10,500 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | D | 0.00 | 116,501 | 0 | 0 | 116.5 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | D | 0.00 | 14,077 | 0 | 116,501 | 130.6 K to 116.5 K (-10.78 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 4.03 | 240,912 | 970,875 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 3.77 | 170,993 | 644,644 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 5.06 | 70,187 | 355,146 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 5.76 | 327,720 | 1,887,339 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 10.22 | 71,369 | 729,248 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 6.04 | 60,000 | 362,400 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 7.14 | 236,810 | 1,690,823 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | D | 7.98 | 18,750 | 149,700 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | D | 0.00 | 233,126 | 0 | 0 | 233.1 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | D | 0.00 | 90,902 | 0 | 233,126 | 324 K to 233.1 K (-28.05 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Sell | D | 0.00 | 12,360 | 0 | 0 | 12.4 K to 0 (-100.00 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Sell | D | 0.00 | 62,647 | 0 | 12,360 | 75 K to 12.4 K (-83.52 %) |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 3.53 | 38,156 | 134,691 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 5.06 | 24,947 | 126,232 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 4.76 | 21,562 | 102,635 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | D | 5.88 | 27,000 | 158,760 | 0 | |
| Mar 11 2020 | FOMX | Foamix Pharmaceuti ... | BARBARI SHARON SURREY | Director | Option Exercise | D | 2.66 | 49,412 | 131,436 | 0 | |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Grant | A | 2.68 | 1,761 | 4,715 | 98,232 | 96.5 K to 98.2 K (+1.83 %) |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Grant | A | 2.68 | 4,705 | 12,598 | 324,028 | 319.3 K to 324 K (+1.47 %) |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Option Exercise | A | 3.53 | 12,719 | 44,898 | 12,719 | |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Grant | A | 0.00 | 14,164 | 0 | 42,359 | 28.2 K to 42.4 K (+50.24 %) |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | A | 3.53 | 38,156 | 134,691 | 38,156 | |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Grant | A | 0.00 | 21,246 | 0 | 58,744 | 37.5 K to 58.7 K (+56.66 %) |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Grant | A | 0.00 | 42,493 | 0 | 111,858 | 69.4 K to 111.9 K (+61.26 %) |
| Mar 03 2020 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Grant | A | 0.00 | 5,312 | 0 | 75,007 | 69.7 K to 75 K (+7.62 %) |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Option Exercise | A | 4.03 | 96,365 | 388,351 | 96,365 | |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Grant | A | 0.00 | 41,299 | 0 | 112,081 | 70.8 K to 112.1 K (+58.35 %) |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Option Exercise | A | 4.03 | 96,365 | 388,351 | 96,365 | |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Grant | A | 0.00 | 41,299 | 0 | 103,636 | 62.3 K to 103.6 K (+66.25 %) |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | A | 4.03 | 96,365 | 388,351 | 96,365 | |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Grant | A | 0.00 | 41,299 | 0 | 96,471 | 55.2 K to 96.5 K (+74.85 %) |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Option Exercise | A | 4.03 | 96,365 | 388,351 | 96,365 | |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Grant | A | 0.00 | 41,299 | 0 | 130,578 | 89.3 K to 130.6 K (+46.26 %) |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Option Exercise | A | 4.03 | 240,912 | 970,875 | 240,912 | |
| Feb 24 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Grant | A | 0.00 | 103,248 | 0 | 319,323 | 216.1 K to 319.3 K (+47.78 %) |
| Jan 03 2020 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Payment of Exercise | F | 3.28 | 514 | 1,686 | 62,337 | 62.9 K to 62.3 K (-0.82 %) |
| Jan 03 2020 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Payment of Exercise | F | 3.28 | 618 | 2,027 | 55,172 | 55.8 K to 55.2 K (-1.11 %) |
| Jan 03 2020 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Payment of Exercise | F | 3.28 | 2,751 | 9,023 | 216,075 | 218.8 K to 216.1 K (-1.26 %) |
| Dec 03 2019 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Grant | A | 2.16 | 9,842 | 21,249 | 218,826 | 209 K to 218.8 K (+4.71 %) |
| Dec 03 2019 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Grant | A | 2.16 | 9,842 | 21,249 | 73,282 | 63.4 K to 73.3 K (+15.51 %) |
| Dec 03 2019 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Grant | A | 2.16 | 4,284 | 9,249 | 55,790 | 51.5 K to 55.8 K (+8.32 %) |
| Nov 05 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | M | 0.62 | 32,500 | 20,150 | 0 | |
| Nov 05 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Buy | M | 0.62 | 32,500 | 20,150 | 182,500 | 150 K to 182.5 K (+21.67 %) |
| Oct 17 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | M | 0.62 | 90,000 | 55,800 | 32,500 | |
| Oct 17 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Buy | M | 0.62 | 90,000 | 55,800 | 150,000 | 60 K to 150 K (+150.00 %) |
| Oct 02 2019 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Payment of Exercise | F | 3.07 | 2,256 | 6,926 | 208,984 | 211.2 K to 209 K (-1.07 %) |
| Sep 11 2019 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | S | 3.50 | 34,392 | 120,375 | 89,279 | 123.7 K to 89.3 K (-27.81 %) |
| Sep 11 2019 | FOMX | Foamix Pharmaceuti ... | Hadar Ilan | CFO & Country Manag ... | Sell | S | 3.50 | 9,420 | 32,991 | 123,671 | 133.1 K to 123.7 K (-7.08 %) |
| Aug 28 2019 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | S | 3.27 | 7,049 | 23,050 | 37,498 | 44.5 K to 37.5 K (-15.82 %) |
| Aug 28 2019 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | S | 3.27 | 7,049 | 23,050 | 37,498 | 44.5 K to 37.5 K (-15.82 %) |
| Aug 14 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Option Exercise | M | 0.62 | 60,000 | 37,200 | 122,500 | |
| Aug 14 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Buy | M | 0.62 | 60,000 | 37,200 | 60,000 | 0 to 60 K |
| Jul 17 2019 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | S | 2.31 | 808 | 1,866 | 44,547 | 45.4 K to 44.5 K (-1.78 %) |
| Jul 08 2019 | FOMX | Foamix Pharmaceuti ... | STERN STANLEY | Director | Grant | A | 0.00 | 28,195 | 0 | 28,195 | 0 to 28.2 K |
| Jul 03 2019 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | S | 2.35 | 639 | 1,502 | 51,969 | 52.6 K to 52 K (-1.21 %) |
| Jul 03 2019 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | S | 2.35 | 3,355 | 7,884 | 211,240 | 214.6 K to 211.2 K (-1.56 %) |
| Jul 03 2019 | FOMX | Foamix Pharmaceuti ... | Stuart Iain | Chief Scientific Of ... | Sell | S | 2.35 | 951 | 2,235 | 63,524 | 64.5 K to 63.5 K (-1.47 %) |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | Bruno Anthony D | Director | Grant | A | 0.00 | 28,195 | 0 | 69,695 | 41.5 K to 69.7 K (+67.94 %) |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Option Exercise | A | 2.66 | 49,412 | 131,436 | 49,412 | |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Sell | S | 2.61 | 10,600 | 27,666 | 45,355 | 56 K to 45.4 K (-18.94 %) |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | KAZANCHYAN ANNA | Director | Grant | A | 0.00 | 28,195 | 0 | 55,955 | 27.8 K to 56 K (+101.57 %) |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | Hirsch Stanley | Director | Grant | A | 0.00 | 56,391 | 0 | 69,365 | 13 K to 69.4 K (+434.65 %) |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | Bright Rex | Director | Option Exercise | A | 2.66 | 49,412 | 131,436 | 49,412 | |
| May 20 2019 | FOMX | Foamix Pharmaceuti ... | BARBARI SHARON SURREY | Director | Option Exercise | A | 2.66 | 49,412 | 131,436 | 49,412 | |
| Apr 03 2019 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Sell | S | 3.75 | 2,519 | 9,446 | 52,608 | 55.1 K to 52.6 K (-4.57 %) |
| Apr 03 2019 | FOMX | Foamix Pharmaceuti ... | Domzalski David | CEO | Sell | S | 3.75 | 5,096 | 19,110 | 214,595 | 219.7 K to 214.6 K (-2.32 %) |
| Mar 06 2019 | FOMX | Foamix Pharmaceuti ... | Wiley Matthew T. | Chief Commercial Of ... | Buy | P | 3.76 | 13,440 | 50,534 | 63,440 | 50 K to 63.4 K (+26.88 %) |
| Jan 03 2019 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Option Exercise | A | 3.77 | 70,297 | 265,020 | 70,297 | |
| Jan 03 2019 | FOMX | Foamix Pharmaceuti ... | Harsch Mutya | CLO and General Cou ... | Grant | A | 0.00 | 30,127 | 0 | 55,127 | 25 K to 55.1 K (+120.51 %) |
| Dec 06 2018 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Buy | P | 3.88 | 12,200 | 47,373 | 112,200 | 100 K to 112.2 K (+12.20 %) |
| Dec 06 2018 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Buy | P | 3.92 | 50,000 | 195,800 | 100,000 | 50 K to 100 K (+100.00 %) |
| Dec 06 2018 | FOMX | Foamix Pharmaceuti ... | Schwartz Aharon | Director | Buy | P | 3.89 | 50,000 | 194,600 | 50,000 | 0 to 50 K |